Global Clidinium Bromide Market Insights, Forecast to 2028

Clidinium bromide (INN) is an anticholinergic (specifically a muscarinic antagonist) drug. It may help symptoms of cramping and abdominal/stomach pain by decreasing stomach acid, and slowing the intestines.
Market Analysis and Insights: Global Clidinium Bromide Market
Due to the COVID-19 pandemic, the global Clidinium Bromide market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Hospital accounting for % of the Clidinium Bromide global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Peptic Ulcer Disease segment is altered to an % CAGR throughout this forecast period.
China Clidinium Bromide market size is valued at US$ million in 2021, while the US and Europe Clidinium Bromide are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Clidinium Bromide landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Clidinium Bromide include Roche, Solitaire Pharma, Apotex, Mediphar, Sanbe Farma, AA Pharma, Hikma, Krka-Pak and Teva, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Clidinium Bromide Scope and Segment
Clidinium Bromide market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Clidinium Bromide market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Hospital
Drug Store
Segment by Application
Peptic Ulcer Disease
GI Motility Disturbances
Acute Enterocolitis
By Company
Roche
Solitaire Pharma
Apotex
Mediphar
Sanbe Farma
AA Pharma
Hikma
Krka-Pak
Teva
Aamorb Pharmaceuticals
Sun Pharmaceutical
Hua Shin
Crescent Pharma
Ying Yuan
Mylan
IFET
Menarini
Bausch Health
Pharmaco
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE